Early Bird Prime for March 15, 2026

The pharmacy giant CVS Health $CVS ( ▲ 0.08% ) has experienced a 15.91% increase over the past 12 months. But just as things were looking good for the company, 2026 began with a slight decline.

This past week, a Bernstein analyst upgraded CVS to "Outperform," raising the price target to $94 from $91. Why the sudden optimism? Well, it seems the 2026 pharmacy benefit manager (PBM) reforms are like a breath of fresh air for CVS. These reforms are all about transparency and cost control in Medicare Part D, which is apparently great news for CVS.

CVS management is now on a mission to refocus on cost control, mix discipline, and integrate recent healthcare services acquisitions. It’s like they’re trying to whip the company into shape for a marathon, with a particular focus on restoring margins in Medicare Advantage and care delivery.

But there’s an issue facing CVS. Pharmacy benefit managers are under the microscope, facing regulatory and political scrutiny from the Department of Labor and Congress. This scrutiny could compress PBM economics or force some dramatic business-model changes.

Should you buy or avoid CVS Health’s stock right now in 2026? Here’s the answer…

logo

Subscribe to Early Bird Prime to read the rest.

Become a paying subscriber of Early Bird Prime to get access to this post and other subscriber-only content.

Upgrade

A subscription gets you:

  • Expert analysis on the best stocks.
  • Stock price predictions based on machine learning.
  • Investing picks and recommendations.
  • Advertisement-free.

Early Bird